Brad Hively: Yeah, sure. We’ve been spending a lot of time focused on clinical research. We think it’s a real differentiator of TOI’s business model. Also we think there’s a lot of untapped potential even though we are very advanced much further along than most community oncology practices. With respect to clinical research, we’ve seen examples of community practices out there that are further along than we are. And so we endeavor to be the best. And so we’ve set really high targets and goals for our clinical research department. Some of the things that we have done we’ve rebranded the entire division. We used to call it ICRI innovative clinical research. We rebranded that TOI clinical research, which we think is more understandable from a patient perspective.
And we’ve also changed a lot of our processes and protocols around patient identification so that we can start talking to patients earlier about clinical trials that they may be eligible for. We have very aggressive growth targets. So we will see — we expect a lot of growth throughout 2023. We started the year strong so that feels good. But those are some of the things that we’re doing around TOI clinical research.
Sandy Draper: Great. Thanks.
Operator: Your next question comes from Gary Taylor with Cowen & Company. Please go ahead.
Gary Taylor: Hi, guys. A couple of questions. One just on the 2023 revenue guidance. How much of that pickup year-over-year $40 million to $70 million pickup is already sort of in the bag if you will because of the acquisitions that have closed and you just get the pickup to the true or the annual run rate in 2023?
Brad Hively: Yeah. I mean we exited 2022 with — if you look at our fourth quarter revenue about $284 run rate. So that’s a significant portion of the way there already just with our exit run rate. Fourth quarter is a little bit stronger. There’s a bit of seasonality so it’s not a perfect annualization, but that gives you a sense.
Gary Taylor: Okay. I didn’t know if the deals were in there for the full — all the deals were in there for the full fourth quarter or not. But that’s helpful. On your new gain share contracts so the three in Florida was one of those with ChenMed or all those with ChenMed, or what are different payers are providing?
Brad Hively: Just one of those was with ChenMed, yeah.
Gary Taylor: And is that like single county kind of a pilot? I mean, obviously there are multiple counties, multiple states. So is there — what’s the outlook that that relationship could get larger?
Brad Hively: Yeah. I mean, we have a lot of optimism for that relationship. We’ve started partnering with them in Central Florida. And we hope to expand that to many other locations but the initial focus is Central Florida. And then, we’ll follow that on with other places for example South Florida and elsewhere where we have market overlap with ChenMed.
Gary Taylor: And then the $59 million of non-current investments, I presume, just because you’ve got plenty of liquidity and maybe more than you’ll put to use right away made more sense to do something that would earn a little more. Can you tell us what that’s in?